Ovarian cancer is a significant contributor to cancer-related mortality among women worldwide. However, because ovarian cancer is often undiagnosed until late in the disease's progression, it is also the fifth leading cancer-related cause of death among women in the US¹. Metastasis remains a major challenge, as it often leads to more aggressive disease and poorer prognosis. Understanding the molecular changes that occur during the transition from primary to metastatic tumors is crucial for developing targeted therapies and improving patient outcomes.